Adding lenvatinib to pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab alone in PD-L1 CPS ≥1 disease. Overall survival was not improved at 21.3 ...

L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.

Investigators sought to determine whether adding gedatolisib to fulvestrant, with or without palbociclib, improved clinical outcomes in patients with HR-positive/HER2-negative/PIK3CA wild-type ...

Investigators conducted a retrospective analysis on the efficacy and safety of first-line bendamustine and rituximab in patients with Waldenström macroglobulinemia.

A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS versus placebo in high-grade uterine sarcomas. Median PFS was identical at 3.7 ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

Please provide your email address to receive an email when new articles are posted on . The addition of pyrotinib to trastuzumab and docetaxel improved 4-year OS vs. placebo for patients with ...

The Personal Financial Specialist (PFS) certification helps Certified Public Accountants (CPAs) demonstrate an expertise in all aspects of wealth management. A PFS is someone with a CPA who also ...

Patients with ER-positive, HER2-negative, ESR1-mutant advanced breast cancer experienced improvements in progression-free survival when being treated with Orserdu, study results showed. Findings from ...

SAN FRANCISCO -- Frontline dual immunotherapy significantly improved progression-free survival (PFS) versus chemotherapy in microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) ...